• Defining robust, standardized proteomics methodologies, from sample collection and analysis to statistical protocols and generation of biomedical conclusions
• Developing a collaborative database to facilitate secure data visualization and sharing, maximizing the impact of available data
• Establishing collaborative projects amongst consortiums, academia, and industry to utilize existing datasets and generate a deeper understanding of proteomics to direct therapeutic development

Speakers:

Harris Bell-Temin

Director

Johnson & Johnson

Nikolai Slavov

Professor

Northeastern University

Satya Saxena

Head, Global Proteomics

Eisai